Navigation Links
ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2010
Date:4/1/2011

$796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due to the recognition of $751,000 in unamortized licensing fees from the termination of the licensing agreement with Meldex International.

For the year ended December 31, 2010, revenues were $1,557,000, compared to $668,000 for the same period of 2009.  The increase of approximately $889,000 was due primarily to the following factors: an increase of $903,000 in OraDisc™ licensing fees and an increase of $138,000 in Aphthasol® product sales as we did not sell any Aphthasol® finished product to our domestic distributor during 2009.  These increases were partially offset by decreases in Zindaclin® royalty and licensing fees of $87,000 due to our divestiture of this product in June 2010.

Research and Development

Research and development expenses for the fourth quarter of 2010 were $309,000, including $32,000 in share-based compensation, compared to $244,000, including $34,000 in share-based compensation, for the fourth quarter of 2009.  The increase of approximately $65,000 in research and development expenses was primarily due to higher costs of $50,000 associated with the development efforts for our Altrazeal® and OraDisc™ technologies.  

For the year ended December 2010, research and development expenses were $1.26 million, including $136,000 in share-based compensation, compared to $2.25 million, including $320,000 in share-based compensation, for the same period in 2009. The decrease of approximately $992,000 in research and development expenses was due primarily to decreases in direct research costs of $73,000, scientific personnel costs of $561,000, clinical testing expenses for our wound care technologies of $163,000, and regulatory consulting of $195,000.

Selling, general and administrative

Selling, general and admini
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
2. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
3. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
4. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
5. ULURU Inc. to Raise $500,000 in Registered Direct Offering
6. ULURU Inc. Reports Third Quarter 2010 Financial Results
7. ULURU Inc. Provides Altrazeal® Clinical Update
8. ULURU Inc. Announces Conference Call
9. ULURU Inc. Reports Second Quarter 2010 Financial Results
10. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
11. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... States Food and Drug Administration ("FDA") said its primary results ... risk of blood clots for women who use drospirenone-containing birth ... safety of Yaz and Yasmin is the subject of approximately ... Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex ...
... BEACH, Calif., Sept. 27, 2011 For the third ... InformationWeek 500 annual listing of the nation,s most innovative ... honored for development and implementation of its Treatment ... communities real-time cost estimates specific to their coverage plan, ...
Cached Medicine Technology:FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 3
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... (HealthDay News) -- Overeating is common during the holidays, but ... an expert says. "Don,t arrive at a party hungry. ... know you,ll be attending a party, but deprivation leads to ... at Northern Westchester Hospital in Mount Kisco, N.Y., said in ... during the day and even to have a snack before ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... FT. WASHINGTON, Pa., Aug. 25 The makers of ZYRTEC(R) ... announced the availability of two new allergy solutions to help ... Children,s ZYRTEC(R) PERFECT MEASURE(R) and ZYRTEC(R) Itchy Eye Drops are ... products. The company also announced the launch of AllergyCast, ...
... Health Care (IQWiG) was commissioned by the Federal Joint ... from taking drugs belonging to the selective serotonin and ... 2 of these drugs have been approved as antidepressants ... final report on 18 August. According to this report, ...
... hyperplastic polyps, sessile serrated polyps (also called sessile serrated ... serrated polyps share molecular features with a subgroup of ... can be precursors of cancer through a hyperplastic polyp ... to arise in the proximal colon. Sessile serrated polyps ...
... Most of the duodenal diverticula are diagnosed incidentally ... Only 5% to 10% of patients with duodenal ... 1% of patients require treatment for various complications ... treatments and operations are considered for the rare ...
... , , , ... of the millions of Americans that have sensitive teeth, you know that ... coffee or a bowl of ice cream. This summer, Tom,s of Maine ... benefit of environmentally sensitive packaging and manufacturing. , , ...
... babies at risk for osteoporosis decades later, study finds , ... preterm with a very low birth weight have significantly lower ... term, a Finnish study has found. , The researchers evaluated ... who were born preterm with very low birth weight. , ...
Cached Medicine News:Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 2Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 4Health News:Antidepressants: Benefit of SNRI is proven 2Health News:Antidepressants: Benefit of SNRI is proven 3Health News:Reinterpretation of proximal colon polyps called hyperplastic in 2001 2Health News:Tom's of Maine is Good to Your Sensitive Teeth and the Planet 2Health News:Tom's of Maine is Good to Your Sensitive Teeth and the Planet 3
... most other EMR,systems require you ... is the only,electronic patient charting,solution ... orthopaedic,workflow. Created around,five specific criteria ... clinic,OrthoPad allows you to see,more ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... EMS provides service to companies in many different ... and restaurants.There are no hidden charges at EMS ... and service are among the lowest in the ... of services ranging from MasterCard/Visa processing to Debit ...
Medicine Products: